GlassScriptPhysician profile
Alaa Alsakaty
NPI 1518495092
$2,112.82
in general payments reported to CMS, 2019-2025
15 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $155 · 2024: $449 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013 · Education: $99.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.02 |
| Education | $99.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $767.35 | 2024-2025 | Krystexxa, Otezla, Otezla |
| Janssen Biotech, INC. | $296.88 | 2023-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $269.82 | 2023-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $143.66 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $122.29 | 2024-2025 | Acthar |
| Genzyme Corporation | $103.30 | 2025 | |
| Radius Health, INC. | $77.74 | 2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $60.95 | 2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $56.97 | 2024-2025 | Orencia |
| Ucb, INC. | $50.29 | 2025 | Bimzelx |
| Genentech USA, INC. | $43.91 | 2024-2025 | Actemra |
| Organon LLC | $34.25 | 2025 | Hadlima |
| Lilly USA, LLC | $34.00 | 2025 | Taltz |
| Sobi, INC | $26.42 | 2025 | |
| Bioventus LLC | $24.99 | 2024 | Supartz Fx Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Alsakaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.